Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Complex E–R relationship, immuno-oncology, single-dose PK model, therapeutic monoclonal antibodies

Recent data from immuno-oncology clinical studies show that the exposure–response (E–R) relationship for therapeutic monoclonal antibodies (mAbs) is often confounded by various factors. The complex interplay involves patient characteristics, disease, drug exposure, clearance, and…

Jun 18^th • 30 mins read

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

monoclonal antibodies, E-R analyses, tumour growth inhibition, drug development

Dose selection and optimization is crucial in drug development to maximize benefits for all patients. Exposure–response (E-R) analysis is useful for dose-selection strategy, but in oncology, prognostic factors can confound the analysis, especially for monoclonal antibodies. The review addr…

Nov 20^th • 12 mins read